A hypersensitivity reaction (HSR), defined as any immunological response to a drug resulting in an adverse reaction, is a frequent side effect during paclitaxel infusion (Zanotti and Markman, 2001). Symptoms vary from mild pruritus to anaphylaxis (Weiss et al., 1990). The occurrence of HSRs can be influenced by administration of an appropriate premedication. Oral premedication with dexamethasone at a dose of 20 mg given orally at 12 and 6 h before infusion of paclitaxel has been shown to reduce the incidence of paclitaxel-induced HSRs significantly (Weiss et al., 1990; Rowinsky and Donehower, 1995; Kintzel, 2001). However, due to logistical factors, short-course premedication with intravenously (i.v.) administered dexamethasone given 30 min prior to paclitaxel infusion has become customary in many centres. Retrospective analyses comparing the effectiveness of both prophylactic regimens have been performed. However, outcomes from these studies are inconsistent. In this report, the rationale of short-course i.v. dexamethasone is discussed at the occasion of a fatal anaphylactic event after paclitaxel infusion with the latter premedication regimen.

CASE REPORT
A 52-year-old male with good performance status was referred for treatment of biopsy-proven non-small-cell lung cancer (NSCLC). The primary lesion was located in the left upper lobe with multiple pleural metastases and thoracoscopic invasion of the mediastinum. The patient was offered palliative chemotherapy consisting of paclitaxel (200 mg/m$^2$) as a 3-hourly infusion followed by carboplatin (area under curve 6) infusion, both as 3-weekly cycles. Premedication consisted of i.v. administered clemastine (2 mg), ranitidine (50 mg) and dexamethasone (10 mg), and was given 30 min prior to paclitaxel infusion. Shortly after the start of the paclitaxel infusion, the patient complained of acute progressive pain in his lower back, breathlessness and chest pain. He developed general distress, followed by cardiac arrest. Cardiopulmonary resuscitation, which included intubation and respiratory support, was started without delay and remained unsuccessful. An autopsy was performed confirming the presence of a stage IV NSCLC extending beyond the parietal pleura into the adjacent soft tissue. Additional findings included mild left ventricular hypertrophy and biventricular dilatation with moderate atherosclerosis of the coronary arteries. Other causes of acute death, such as myocardial infarction, could be excluded. The spleen and liver were congested, consistent with fluid accumulation in the third space.

DISCUSSION
In this report, we describe the fatal outcome of an acute-onset HSR after paclitaxel infusion, despite administration of a widely accepted regimen of premedication. Postmortem findings after anaphylactic reactions and especially medication-induced anaphylaxis are generally nonspecific and include pulmonary congestion and oedema. Findings indicating an immunological (allergic) cause of death as cutaneous erythema, upper airway oedema and petechial haemorrhages are rarely seen (Pumphrey and Roberts, 2000).

Paclitaxel is widely used as antitumour medication in ovarian, breast, non-small-cell lung and other cancers. Owing to the poor insolubility of paclitaxel, the compound requires dissolution in Cremophor EL, a derivative of castor oil. Although the incidence of HSR after paclitaxel infusion is estimated to be <44 and <10% for mild and severe HSRs, respectively, fatal outcome is rare (Weiss et al., 1990). It is known...
that HSRs predominantly occur during the first 10 min of infusion and are usually restricted to the first two cycles of chemotherapy.

The aetiology of paclitaxel-associated HSR is multifactorial and several mechanisms have been postulated: (A) an IgE-mediated mast-cell degranulation induced by paclitaxel (Weiss et al., 1990) or Cremophor EL (Dye and Watkins, 1980; Weiss and Baker, 1987); (B) a non-IgE-mediated idiosyncratic mast-cell degranulation by paclitaxel or by Cremophor EL (Gelderblom et al., 2001) and (C) complement activation (Szegedi et al., 2001). The rapid and overwhelming onset of the HSR as observed in our patient is not compatible with the natural course of an IgE hypersensitivity reaction and points towards one of the two other mechanisms.

Dexamethasone is a long-acting glucocorticoid with a biologic half-life of approximately 48 h and noticeable onset of biologic activity after several hours (O'Sullivan et al., 1997). Dexamethasone strongly inhibits inflammation, especially cellular-mediated immunity and the production or action of the local mediators of inflammation, such as the prostaglandins and lymphotoxins. Furthermore, dexamethasone reduces vascular permeability and maintains normal vascular responsiveness to circulating vasoconstrictor factors. Standard premedication with dexamethasone at a dose of 20 mg given orally 12 and 6 h prior to paclitaxel infusion has been shown to prevent HSR in most cases (Weiss et al., 1990; Rowinsky and Donehower, 1995; Kintzel, 2001). Despite this premedication schedule, grade 3/4 HSR still occur in 1–2% of patients (Kosmidis et al., 2002).

However, this treatment regimen requires a good compliance by the patients. To avoid rescheduling chemotherapy schemes due to noncompliance, attention was focused on anecdotal cases in which dexamethasone was administered shortly before paclitaxel infusion. In several retrospective series, 5–20 mg of dexamethasone administered i.v. 3 min before the infusion of paclitaxel showed equal success as the oral premedication of historical cases (Parikh et al., 1996; Bookman et al., 1997; Micha et al., 1998; Markman et al., 1999; Kintzel, 2001). These reports are in contrast with a recent report by Kwon et al. (2002), who retrospectively showed that a single-dose i.v. corticosteroid prophylactic regimen was associated with a significantly higher rate of HSR than the two-dose oral corticosteroid regimen. Bearing in mind the pharmacological properties of dexamethasone, the short-course i.v. premedication schedule given 30 min before paclitaxel infusion is unlikely to result in an adequate level of immunosuppression during the infusion of the drug. This may explain the results of Kwon et al. This is confirmed by the observation that the incidence of HSRs is not influenced by the dosage of i.v. administered dexamethasone 30 min before chemotherapy infusion (Koppler et al., 2001). It is possible that retrospective analysis and comparison of the study cohort with historical controls bias the observed protective effect of short-course i.v. prophylaxis by dexamethasone. A prospective randomised study in which the oral pre-treatment regimen is compared with the short-course i.v. administration of dexamethasone is preferable.

In conclusion, the fatal outcome of the paclitaxel-associated HSR in the patient illustrates the need for continuous awareness and questions the importance of routine i.v. premedication for paclitaxel administration.

REFERENCES

Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF (1997) Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8: 611–614

Dye D, Watkins J (1980) Suspected anaphylactic reaction to Cremophor EL. BMJ 280: 1353

Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle detection for drug formulation. Eur J Cancer 37: 1590–1598

Kintzel PE (2001) Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 35: 1114 – 1117

Koppler H, Heymanns J, Weide R (2001) Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie 24: 283 – 285

Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos Ch, Samantas E, Boukvinas J, Fountzilas G, Skarlos D, Economopoulos Th, Tsavdaridis D, Papakostas P, Bacoziannis Ch, Dimopoulou M (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20: 3578 – 3585

Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K (2002) A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 88: 420 – 425

Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (1999) An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 125: 427 – 429

Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV (1998) Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 69: 122 – 124

O'Sullivan BT, Cutler DJ, Hunt GE, Walters C, Johnson GF, Catherson ID (1997) Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol Psychiatry 41: 574 – 584

Parikh B, Khanolkar S, Advani SH, Dhabhar B, Chandra M (1996) Safety profile of single-dose dexamethasone premedication for paclitaxel. J Clin Oncol 14: 2189 – 2190

Pumphrey RSH, Roberts ISO (2000) Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 53: 273 – 276

Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332: 1004 – 1014

Szegedi J, Alving CR, Savay S (2001) Formation of complement-activating particles in aqueous solutions of taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 1: 721 – 735

Weiss RB, Baker JR (1987) Hypersensitivity reactions from antineoplastic agents. Cancer Metastas Rev 6: 413 – 432

Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263 – 1268

Zanotti KM, Markman M (2001) Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 24: 767 – 779